CAMP4 Therapeutics Corp [CAMP] stock is trading at $7.13, up 1.71%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The CAMP shares have gain 24.65% over the last week, with a monthly amount glided 78.70%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
CAMP4 Therapeutics Corp [NASDAQ: CAMP] stock has seen the most recent analyst activity on October 02, 2025, when Cantor Fitzgerald initiated its Overweight rating and assigned the stock a price target of $7. Previously, JP Morgan downgraded its rating to Neutral on September 16, 2025. On May 27, 2025, Wedbush initiated with an Outperform rating and assigned a price target of $8 on the stock. William Blair started tracking the stock assigning an Outperform rating. Piper Sandler initiated its recommendation with an Overweight and recommended $18 as its price target on November 05, 2024. JP Morgan started tracking with an Overweight rating for this stock on November 05, 2024, and assigned it a price target of $23.
CAMP4 Therapeutics Corp [CAMP] stock has fluctuated between $1.30 and $7.69 over the past year. Currently, Wall Street analysts expect the stock to reach $7 within the next 12 months. CAMP4 Therapeutics Corp [NASDAQ: CAMP] shares were valued at $7.13 at the most recent close of the market. An investor can expect a potential drop of -1.82% based on the average CAMP price forecast.
Analyzing the CAMP fundamentals
Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at -14.02%, Pretax Profit Margin comes in at -14.04%, and Net Profit Margin reading is -14.04%. To continue investigating profitability, this company’s Return on Assets is posted at -0.62, Equity is -1.0 and Total Capital is -0.68. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.11.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 6.77 points at the first support level, and at 6.40 for the second support level. However, for the 1st resistance point, the stock is sitting at 7.40, and for the 2nd resistance point, it is at 7.67.
Ratios To Look Out For
For context, CAMP4 Therapeutics Corp’s Current Ratio is 9.83. Also, the Quick Ratio is 9.83, while the Cash Ratio stands at 9.52. Considering the valuation of this stock, the price to sales ratio is 87.96, the price to book ratio is 5.70.
Transactions by insiders
Recent insider trading involved 5AM Partners VI, LLC, 10% Owner, that happened on Sep 11 ’25 when 2.94 million shares were purchased. 10% Owner, Polaris Management Co. VII, L. completed a deal on Sep 11 ’25 to buy 1.31 million shares. Meanwhile, Director Nashat Amir bought 1.31 million shares on Sep 11 ’25.
